Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral tablet, ASC30, in obese individuals.

The study, which involved 40 obese subjects under fasting conditions, included five cohorts with various doses of the tablet.